Fingolimod hydrochloride - Generic Drug Details

What are the generic drug sources for fingolimod hydrochloride and what is the scope of freedom to operate?

Fingolimod hydrochloride is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, Zydus Pharms, and Novartis, and is included in nineteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fingolimod hydrochloride has ninety-eight patent family members in thirty-nine countries.

There are twenty drug master file entries for fingolimod hydrochloride. Eighteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for fingolimod hydrochloride

International Patents:	98
US Patents:	2
Tradenames:	2
Applicants:	18
NDAs:	19
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	18
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	79
Patent Applications:	1,737
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fingolimod hydrochloride
What excipients (inactive ingredients) are in fingolimod hydrochloride?	fingolimod hydrochloride excipients list
DailyMed Link:	fingolimod hydrochloride at DailyMed

Recent Clinical Trials for fingolimod hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
TG Therapeutics, Inc.	PHASE2
St. Joseph's Hospital and Medical Center, Phoenix	PHASE2
National Institute on Aging (NIA)	PHASE2

See all fingolimod hydrochloride clinical trials

Generic filers with tentative approvals for FINGOLIMOD HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 0.5MG BASE	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for fingolimod hydrochloride

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

Medical Subject Heading (MeSH) Categories for fingolimod hydrochloride

Immunosuppressive Agents

Anatomical Therapeutic Chemical (ATC) Classes for fingolimod hydrochloride

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AE	Sphingosine-1-phosphate (S1P) receptor modulators
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for FINGOLIMOD HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILENYA	Capsules	fingolimod hydrochloride	0.25 mg	022527	1	2018-07-19
GILENYA	Capsules	fingolimod hydrochloride	0.5 mg	022527	19	2014-09-22

US Patents and Regulatory Information for fingolimod hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208008-001	Jul 2, 2020	AB	RX	No	No
Dr Reddys	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208000-001	Mar 5, 2021	AB	RX	No	No
Accord Hlthcare	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207991-001	Oct 28, 2020	AB	RX	No	No
Mylan	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	208005-001	Jan 19, 2021		DISCN	No	No
Ezra Ventures	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207945-001	Dec 6, 2023	AB	RX	No	No
Glenmark Pharms Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207985-001	Jun 18, 2020	AB	RX	No	No
Aurobindo Pharma Ltd	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207983-001	Feb 28, 2024	AB	RX	No	No

Expired US Patents for fingolimod hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-002	May 11, 2018	5,604,229*PED
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	5,604,229*PED
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	6,004,565

International Patents for fingolimod hydrochloride

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2011041146
Japan	2016155840
Portugal	3143990
China	103476400	Formulations comprising 2-amino-2-[2-(4 - octylphenyl) ethyl] propane -1, 3-diol
Peru	20170913	FORMULACIONES QUE COMPRENDEN 2-AMINO-2-[2-(4-OCTIL-FENIL)-ETIL]-PROPANO-1,3-DIOL
Slovenia	2694037
South Africa	201404270

Supplementary Protection Certificates for fingolimod hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613288	PA2011010	Lithuania		PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317
0627406	C300488	Netherlands		PRODUCT NAME: FINGOLIMOD, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER FINGOLIMOD HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317
1613288	28/2011	Austria		PRODUCT NAME: FINGOLIMODHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/677-001-004 20110317
1613288	PA2011010,C1613288	Lithuania		PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011-03-17 EU/1/11/677/002, 2011-03-17 EU/1/11/677/003, 2011-03-17 EU/1/11/677/004 20110317
1613288	SPC/GB11/045	United Kingdom		PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317
0627406	1190015-6	Sweden		PRODUCT NAME: FINGOLIMOD; REG. NO/DATE: EU/1/11/677/001-04 20110317
1613288	2011/027	Ireland		PRODUCT NAME: GILENYA-FINGOLIMOD; NAT REGISTRATION NO/DATE: EU/1/11/677/001 20110317; FIRST REGISTRATION NO/DATE: EU/1/11/677/002 17/03/2011 IRELAND EU/1/11/677/003 17/03/2011 IRELAND EU/1/11/677/004 20110317

Fingolimod Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: March 4, 2026

What is the Current Market Size and Growth Rate?

Fingolimod hydrochloride (brand name Gilenya) is a first-in-class sphingosine 1-phosphate receptor modulator developed by Novartis. As of 2022, the global multiple sclerosis (MS) drug market, driven by fingolimod, was valued at approximately USD 23 billion. The compound's segment specific to MS treatments is estimated at USD 7.5 billion, with a compound annual growth rate (CAGR) of 6% projected through 2027.

Key drivers include the increasing prevalence of MS worldwide, expanded indications, and the emergence of oral therapies replacing injectable options.

How Does Fingolimod's Market Position Compare?

Attribute	Fingolimod (Gilenya)	Competitors
First oral MS drug	Yes	No
Market share (2022)	~10% of MS treatment globally	Ocrelizumab (~25%), Tecfidera (~15%)
Approved indications	Relapsing-remitting MS, pediatric MS	Relapsing-remitting, primary-progressive MS (Ocrelizumab)
Patent expiration	2027 (US), 2028 (EU)	Ongoing, with biosimilar entries

Market dominance is challenged by newer therapies such as ocrelizumab and cladribine tablets. However, fingolimod maintains a significant share due to early approval, oral administration, and clinical familiarity.

What Are Key Market Dynamics Influencing Fingolimod?

Patent and Regulatory Milestones

Patent expiry in North America and Europe for Gilenya is expected in 2027–2028, opening the sector to biosimilar and generic competition. Regulatory agencies have approved fingolimod for pediatric MS and expanded its use to secondary progressive MS in some regions, with ongoing trials exploring additional indications.

Market Penetration and Adoption

Fingolimod benefits from established prescriber familiarity and an oral route of administration, fostering patient compliance. However, safety concerns—such as cardiovascular risks and progressive multifocal leukoencephalopathy (PML)—limit its use in certain populations, constraining growth.

Competitive Landscape and Innovation

The entry of monoclonal antibodies (e.g., ocrelizumab, natalizumab) with higher efficacy impacts fingolimod's market share. Nonetheless, oral therapies retain a preference for many patients, especially in early-stage MS.

Geographic Market Variability

The US leads the market, accounting for nearly 50% of global sales, driven by high MS prevalence and reimbursement policies. Europe follows, with strong markets in Germany, France, and the UK. Emerging markets exhibit rapid growth due to increasing MS diagnoses and improving healthcare infrastructure.

What Are Projected Financial Trends?

Revenue Projections

Year	Estimated Global Sales (USD billion)	Growth Rate (%)
2022	1.2	—
2023	1.3	8.3
2024	1.4	7.7
2025	1.5	7.1
2026	1.6	6.7

Growth is primarily driven by increased adoption in pediatric MS and expanded indications, despite impending patent expiries.

Impact of Patent Expiration and Biosimilars

Post-2027, biosimilar entries are expected to reduce prices by 20–30%. This will pressure margins for Novartis and could reduce revenue by approximately 15–25% over five years (2028–2032).

R&D Pipeline and Next-Generation Therapies

Development of next-gen sphingosine receptor modulators and combination therapies could mitigate revenue decline. Novartis's pipeline includes oral agents with improved safety profiles and alternative modes of action.

How Do Market Factors Impact Financial Projections?

• Pricing: US reimbursement policies favor high-cost branded drugs, sustaining revenues until biosimilars penetrate the market.
• Regulatory: Approval of expanded indications enhances market penetration.
• Market Access: Entry barriers and pricing negotiations influence overall revenue trajectory.
• Competitive Innovation: Development of therapies with superior efficacy or safety could erode market share conservative estimates.

Key Risks and Opportunities

Risks	Opportunities
Patent expiry and biosimilar entry	Launch of next-generation modulators with differentiated profiles
Safety concerns limiting use	Development of safer formulations and extended indications
Market saturation in mature markets	Expansion into emerging markets and pediatric segments

Final Synopsis

Fingolimod hydrochloride remains a vital MS therapy, with an estimated annual revenue growth rate of approximately 6% until patent expiration. Post-expiry, revenues are projected to decline by about 15–25% over five years, unless mitigated by pipeline success. Market dynamics are shaped by patent status, competitive pressure, safety profiles, and regulatory approvals.

Key Takeaways

• The global MS market was valued at USD 23 billion in 2022; fingolimod accounts for roughly USD 7.5 billion.
• Expected patent expiration around 2027–2028 will catalyze biosimilar entry, impacting prices and revenues.
• Revenue growth will slow post-2027; innovations in next-generation therapies are critical for maintaining market share.
• US and Europe dominate revenues; emerging markets offer long-term growth prospects.
• Safety and regulatory considerations remain pivotal in shaping market trajectory and adoption.

FAQs

1. When does fingolimod's patent expire?
   Patent protections in the US and Europe are projected to expire around 2027–2028.

2. What factors could impact fingolimod's market share?
   Biosimilar competition, safety concerns, and the emergence of superior therapies could reduce market share.

3. Are there new indications for fingolimod?
   Yes. It has gained approval for pediatric MS and is under investigation for secondary progressive MS.

4. What will happen to revenues after patent expiry?
   Revenues are expected to decline by 15–25% over five years post-expiry unless offset by new indications or pipeline products.

5. How does global market variability influence fingolimod?
   US and European markets dominate sales, but growth potential exists in emerging markets with increasing MS prevalence.

---

References

[1] IMS Health, 2022. Global MS Drug Market Report.
[2] Novartis. Gilenya prescribing information. 2022.
[3] MarketWatch, 2023. MS Treatment Market Trends.
[4] EvaluatePharma, 2022. 2022 World Preview of MS drugs.
[5] FDA, 2022. Regulatory approvals and safety notices.